DXD

DXD 제품 목록

  • 속성

    Antibody (3)

  • 제품 라이브러리

    온라인 (3)

  • Mouse (3)

  • 태그

    - (2)Mouse IgG1 (1)

  • 마커

    Unconjugated (1)HRP Labeled (1)Biotin-labeled (1)

DXD분자 배경

Dxd (Exatecan ADC derivative) is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 uM for targeting ADCs (DS-8201A). Dxd was cytotoxic to human tumor cell lines KPL-4, NCI-N87 and SK-BR, 3 and the IC50s of MDA-MB-468 was 1.43 NM-4.07 nM, while lgGADC (Dxd as payload) had no inhibitory effect on HER2 expression in the 4 cell lines. DS8201a (Dxd as payload) had a significant inhibitory effect on HER2-positive KPL-4 and NCI cell lines N87 and SK-BRwith IC50 values of 26.8, 25.4 and 6.7 ng/mL, respectively, but had no inhibitory effect on MDA MB-468 (IC50, > 10000 - mL). HRP-anti-DXD-antibody is a conjugation product of HRP and anti-DXD-antibody. It can be used in PK, PD analysis and ELISA.

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
TifcemalimabTAB-004; JS-004Phase 3 ClinicalShanghai Junshi Biosciences Co LtdSolid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hodgkin Disease; Nasopharyngeal Carcinoma; Lymphoma; Lung Neoplasms; Melanoma; Neoplasm Metastasis
상세
ANB-032ANB-032Phase 2 ClinicalAnaptysbio IncInflammation; Dermatitis, Atopic; Eczema
상세
VenanprubartLY-3361237Phase 2 ClinicalSanford-Burnham Medical Research Institute, Eli Lilly And CompanySjogren's Syndrome; Lupus Erythematosus, Systemic; Psoriasis
상세
MB-272MB272; GS-0272Phase 1 ClinicalUniversity Of OxfordArthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic
상세
HFB-200603HFB-200603Phase 1 ClinicalHiFiBiO TherapeuticsCarcinoma, Renal Cell; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung
상세
  • 제품 목록
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호